Proceedings of the National Academy of Sciences · 2009 · 130 citations · 17 references
PharmacyOncologyPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer BiotechnologyCancer Cell SignalingCancer NanomedicineNanocarriers For TherapeuticsTargeted Cancer TherapyTargeted TherapyCancer NanotherapyExtracellular Signal-regulated Kinase PathwayMapk SignalingNanoparticle DeliveryNanoparticle Delivery VectorsNanoparticle Drug TargetingNanoparticle-based ChemotherapyPoly(lactic-co-glycolic Acid)
The MAPK signal transduction cascade is dysregulated in a majority of human tumors. Here we report that a nanoparticle-mediated targeting of this pathway can optimize cancer chemotherapy. We engineered nanoparticles from a unique hexadentate-polyD,L-lactic acid-co-glycolic acid polymer chemically conjugated to PD98059, a selective MAPK inhibitor. The nanoparticles are taken up by cancer cells through endocytosis and demonstrate sustained release of the active agent, resulting in the inhibition of phosphorylation of downstream extracellular signal regulated kinase. We demonstrate that nanoparticle-mediated targeting of MAPK inhibits the proliferation of melanoma and lung carcinoma cells and induces apoptosis in vitro. Administration of the PD98059-nanoparticles in melanoma-bearing mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy. Our study shows the nanoparticle-mediated delivery of signal transduction inhibitors can emerge as a unique paradigm in cancer chemotherapy.
17
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
Prevalence of ras gene mutations in human colorectal cancers
Johannes L. Bos, Eric R. Fearon, Stanley R. Hamilton et al. · Nature · 1987 · 1.9K citations
Theresa M. Allen, Cecilie Cetti Hansen, Francisco J. Plaza Martín et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 1991 · 1.4K citations